Yibai Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 301 million yuan, a year-on-year decrease of 33.73%; net loss of 709.127 million yuan. The first three quarters of 2026 achieved operating income of 990 million yuan, a year-on-year decrease of 31.57%; net loss of 151 million yuan, after deducting non-net loss of 163 million yuan. The changes in performance were mainly due to a decline in drug sales, a decline in revenue and an increase in losses. On July 10, 2026, the company completed the cancellation of 7,533,500 repurchased shares, accounting for 0.95% of the total share capital before cancellation. The total share capital was changed to 784 million shares, and the registration of industrial and commercial changes was completed on August 24.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.